Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11208061 | 0.79 | GABRA1 (0.50) | GABRA1GABRB2TSHRHPGDPOLB | |
| SCHEMBL639888 | 0.77 | TSHR (0.52) | GABRA1GABRB2TSHRHPGDPOLB | |
| SCHEMBL22144403 | 0.77 | TSHR (0.52) | GABRA1GABRB2TSHRHPGDPOLB | |
| SCHEMBL17038537 | 0.77 | GABRA1 (0.48) | GABRA1GABRB2TSHRHPGDPOLB | |
| SCHEMBL3764158 | 0.77 | ESR1 (0.46) | GABRA1GABRB2TSHRHPGDALDH1A1 | |
| SCHEMBL911040 | 0.76 | GABRA1 (0.58) | GABRA1GABRB2TSHRHPGDPOLB | |
| SCHEMBL8943608 | 0.76 | CES2 (0.48) | ALDH1A1MAPTCYP3A4ALOX15MEN1 | |
| SCHEMBL4840123 | 0.76 | ACP3 (0.43) | TSHRKDM4EALDH1A1MAPTLMNA | |
| SCHEMBL11204715 | 0.76 | GABRA1 (0.46) | GABRA1GABRB2TSHRHPGDPOLB | |
| SCHEMBL30195663 | 0.75 | GABRA1 (0.62) | GABRA1GABRB2TSHRHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1511500-A4 | COMBINATION OF ANTI-MUSCARINIC AGENTS AND NON-GLUCOCORTICOID STEROIDS | EPIGENESIS PHARMACEUTICALS LLC (US) | 2009-04-29 | — | — | EP | claimed |
| JP-2006504666-A | — | — | 2006-02-09 | — | — | JP | claimed |
| CN-1674918-A | Compositions, formulations and kits for treating respiratory and pulmonary diseases using dehydroepiandrosterone steroids and antimuscarinic drugs | EPIGENESIS PHARMACEUTICALS INC (US) | 2005-09-28 | — | — | CN | claimed |
| EP-1511500-A2 | COMBINATION OF ANTI-MUSCARINIC AGENTS AND NON-GLUCOCORTICOID STEROIDS | Epigenesis Pharmaceuticals, Inc. (US) | 2005-03-09 | — | — | EP | claimed |
| WO-2004014293-A2 | COMBINATION OF ANTI-MUSCARINIC AGENTS AND NON-GLUCOCORTICOID STEROIDS | EPIGENESIS PHARMACEUTICALS, INC. (US) | 2004-02-19 | — | — | WO | claimed |
| US-20030216329-A1 | Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s) | EPEGENESIS PHARMACEUTICALS, INC. | 2003-11-20 | — | — | US | claimed |
| US-6284750-B1 | DRUG, COSMETICS STEROID | ESTEE LAUDER INC. | 2001-09-04 | — | — | US | claimed |
| EP-0876391-B1 | NOVEL STEROID ESTERS USEFUL AGAINST SKIN DISORDERS | ESTEE LAUDER INC (US) | 2000-08-16 | — | — | EP | claimed |
| US-6025347-A | Steroid esters useful against skin disorders | ESTEE LAUDER INC. (US) | 2000-02-15 | — | — | US | claimed |
| US-5948418-A | MERCAPTANS | ESTEE LAUDER, INC. (US) | 1999-09-07 | — | — | US | claimed |
| EP-0876391-A4 | NOVEL STEROID ESTERS USEFUL AGAINST SKIN DISORDERS | ESTEE LAUDER INC (US) | 1998-12-30 | — | — | EP | claimed |
| EP-0876391-A1 | NOVEL STEROID ESTERS USEFUL AGAINST SKIN DISORDERS | ESTEE LAUDER INC. (US) | 1998-11-11 | — | — | EP | claimed |
| US-5683705-A | Sulfur-based amides and bis-amides useful against skin disorders | ESTEE LAUDER, INC. (US) | 1997-11-04 | — | — | US | claimed |
| WO-1997010255-A1 | NOVEL STEROID ESTERS USEFUL AGAINST SKIN DISORDERS | ESTEE LAUDER, INC. (US) | 1997-03-20 | — | — | WO | claimed |
| US-6284750-B1 | DRUG, COSMETICS STEROID | ESTEE LAUDER INC. | 2001-09-04 | — | — | US | disclosed |
| EP-0876391-B1 | NOVEL STEROID ESTERS USEFUL AGAINST SKIN DISORDERS | ESTEE LAUDER INC (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6025347-A | Steroid esters useful against skin disorders | ESTEE LAUDER INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-5736537-A | Dehydroep:androsterone sailcylate useful against skin atrophy | ESTEE LAUDER, INC. (US) | 1998-04-07 | — | — | US | disclosed |
| US-5683705-A | Sulfur-based amides and bis-amides useful against skin disorders | ESTEE LAUDER, INC. (US) | 1997-11-04 | — | — | US | disclosed |
| WO-1997010255-A1 | NOVEL STEROID ESTERS USEFUL AGAINST SKIN DISORDERS | ESTEE LAUDER, INC. (US) | 1997-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216329-A1 | Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s) | KIT, NR5A1, CHRM5 | GABRA1 2948/4885GABRB2 4176/4885TSHR 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.